Italy · Delayed Price · Currency is EUR Aerovate Therapeutics Statistics
Total Valuation
BIT:1RBI has a market cap or net worth of EUR 9.89 billion.
| Market Cap | 9.89B |
| Enterprise Value | n/a |
Important Dates
The last earnings date was Wednesday, July 30, 2025.
| Earnings Date | Jul 30, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
| Current Share Class | 328.23M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 126.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 5.89 |
| PS Ratio | 1.13 |
| PB Ratio | 0.47 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -16.79 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 4.47%.
| Return on Equity (ROE) | 4.47% |
| Return on Assets (ROA) | 0.46% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 204,630 |
| Profits Per Employee | -3,063 |
| Employee Count | 43,574 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BIT:1RBI has paid 1.01 billion in taxes.
| Income Tax | 1.01B |
| Effective Tax Rate | 51.61% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 26.04 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 73.63 |
| Average Volume (20 Days) | 50 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BIT:1RBI had revenue of EUR 8.75 billion and -131.00 million in losses. Loss per share was -0.40.
| Revenue | 8.75B |
| Gross Profit | 8.75B |
| Operating Income | 4.58B |
| Pretax Income | 1.95B |
| Net Income | -131.00M |
| EBITDA | n/a |
| EBIT | n/a |
| Loss Per Share | -0.40 |
Balance Sheet
The company has 41.30 billion in cash and 28.13 billion in debt, giving a net cash position of 13.18 billion.
| Cash & Cash Equivalents | 41.30B |
| Total Debt | 28.13B |
| Net Cash | 13.18B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 21.17B |
| Book Value Per Share | 60.65 |
| Working Capital | -113.01B |
Cash Flow
In the last 12 months, operating cash flow was -1.14 billion and capital expenditures -532.00 million, giving a free cash flow of -1.68 billion.
| Operating Cash Flow | -1.14B |
| Capital Expenditures | -532.00M |
| Free Cash Flow | -1.68B |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | 52.29% |
| Pretax Margin | 22.29% |
| Profit Margin | -0.22% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 3.66%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 3.66% |
| Dividend Growth (YoY) | -46.34% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 3.66% |
| Earnings Yield | -1.33% |
| FCF Yield | -16.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |